Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of the study population

From: Factors associated with the 6-minute walk distance in patients with systemic sclerosis

  N Value
Demographic data
 Females, n (%) 298 242 (81.2)
 Age at inclusion (years), mean (SD) 298 58.2 (13.3)
 BMI (kg/m2), mean (SD) 283 24.9 (5.3)
 Smoking history, n (%) 297 119 (40.1)
Diagnosis of SSc
 SSc subtype
  lcSSc, n (%) 298 245 (82.2)
  dcSSc, n (%) 298 53 (17.8)
 Disease duration at inclusion
  Since diagnosis (years), mean (SD) 298 9.1 (8.1)
  Since first non-Raynaud symptom (years), mean (SD) 244 9.9 (8.5)
  Since Raynaud phenomenon onset (years), mean (SD) 279 15.6 (12.2)
 Immunological profile
  Anti-centromere antibodies, n (%) 291 163 (56.0)
  Anti-topoisomerase I antibodies, n (%) 291 57 (19.6)
  Anti-RNA polymerase III antibodies, n (%) 291 7 (2.4)
  Anti-RNP antibodies, n (%) 291 15 (5.2)
 Nailfold capillaroscopy
  Specific organic microangiopathy, n (%) 109 98 (89.9)
History of organ involvement
 Interstitial lung disease
  No ILD, n (%) 270 159 (58.9)
  Limited ILD, n (%) 270 82 (30.4)
  Extensive ILD, n (%) 270 29 (10.7)
 Pulmonary arterial hypertension, n (%) 286 17 (5.9)
 Scleroderma renal crisis, n (%) 285 1 (0.4)
 Digital ulcers (previously or at inclusion), n (%) 298 128 (43.0)
 Acute venous thrombosis, n (%) 297 33 (11.1)
 Acute arterial thrombosis, n (%) 297 39 (13.1)
 Chronic cardiovascular disease, n (%) 296 21 (7.1)
 Clinical evaluation at inclusion
 Modified Rodnan skin score, mean (SD) 297 4.96 (5.95)
 Telangiectasia, n (%) 275 199 (72.4)
 NYHA functional class
  Class I, n (%) 296 132 (44.6)
  Class II, n (%) 296 101 (34.1)
  Class III, n (%) 296 57 (19.3)
  Class IV, n (%) 296 6 (2.0)
 Cardiovascular symptoms, n (%) 298 24 (8.1)
 Joint symptoms, n (%) 296 125 (42.2)
 Muscle symptoms, n (%) 297 57 (19.2)
6-minute walk test
 Total distance (m), mean (SD) 298 438.3 (108.1)
 Total distance (% predicted), mean (SD) 290 81.6 (17.8)
 Initial SpO2 (%), mean (SD) 280 98.1 (2.1)
 Final SpO2 (%), mean (SD) 275 97.5 (3.3)
 ΔSpO2 (%), mean (SD) 276 -0.58 (2.72)
 Initial Borg score, mean (SD) 294 0.4 (1.1)
 Final Borg score, mean (SD) 294 2.5 (2.2)
 ΔBorg score, mean (SD) 293 2.1 (1.9)
 Initial sBP (mmHg), mean (SD) 292 123.8 (16.6)
 Final sBP (mmHg), mean (SD) 292 132.9 (18.2)
 ΔsBP (mmHg), mean (SD) 291 9.2 (14.0)
 Initial dBP (mmHg), mean (SD) 271 97.4 (3.4)
 Final dBP (mmHg), mean (SD) 292 73.6 (10.0)
 ΔdBP (mmHg), mean (SD) 291 0.95 (10.2)
 Initial HR (bpm), mean (SD) 289 76.7 (12.3)
 Final HR (bpm), mean (SD) 288 87.1 (15.9)
 ΔHR (bpm), mean (SD) 288 10.4 (11.2)
Biological data
 Hemoglobin (g/dl), mean (SD) 291 13.4 (1.4)
 ESR (mm/h), mean (SD) 258 14.8 (15.3)
 CRP (mg/L), mean (SD) 293 4.0 (4.7)
 Creatinin (mg/L), mean (SD) 294 8.0 (2.8)
 Estimated GFR (ml/min/1.73 m2), mean (SD) 294 89.1 (21.5)
 Elevated Nt-pro-BNP, n (%) 290 43 (14.8)
 CK (IU), mean (SD) 289 93 (59.5)
 Ferritin (ng/ml), mean (SD) 268 105.5 (136.4)
 Complement activation, n (%) 265 9 (3.4)
Transthoracic echocardiography
 Left ventricular ejection fraction (%), mean (SD) 250 62.8 (6.7)
 Left ventricular diastolic dysfunction, n (%) 229 124 (54.2)
 Valvular heart disease, n (%) 244 41 (16.8)
 Peak TRV (m/s), mean (SD) 98 2.62 (0.54)
 RA–RV pressure gradient (mmHg), mean (SD) 206 27.4 (13.4)
 Estimated sPAP (mmHg), mean (SD) 194 31.5 (13.1)
 RA area (cm2), mean (SD) 139 15.0 (4.6)
 IVC dilation and/or decreased IVC collapse, n (%) 210 16 (7.6)
 Pericardial effusion, n (%) 230 5 (2.2)
Pulmonary function tests
 TLC (% predicted), mean (SD) 276 96.2 (16.4)
 FVC (% predicted), mean (SD) 287 103.5 (21.8)
 FEV1 (% predicted), mean (SD) 286 95.1 (21.8)
 FEV1/FVC (%), mean (SD) 286 79.2 (10.7)
 DLCO (% predicted), mean (SD) 285 70.0 (19.7)
 KCO (% predicted), mean (SD) 278 80.9 (17.6)
Composite scores
 EScSG-AI score, mean (SD) 289 1.16 (1.2)
 Medsger severity score, mean (SD) 228 4.17 (2.5)
 HAQ-DI score, mean (SD) 223 0.61 (0.7)
Treatments
 Negative chronotropic drugs, n (%) 293 87 (29.7)
 Positive chronotropic drugs, n (%) 293 10 (3.4)
  1. BMI body mass index, CK creatin kinase, CRP C-reactive protein, dBP diastolic blood pressure, dc diffuse cutaneous, DLCO diffusing capacity of the lung for carbon monoxide, EScSG-AI European Scleroderma Study Group Activity Index, ESR erythrocyte sedimentation rate, FEV1 forced expiratory volume during the first second, FVC forced vital capacity, GFR glomerular filtration rate, HAQ-DI Health Assessment Questionnaire—Disability Index, HR heart rate, ILD interstitial lung disease, IU international unit, IVC inferior vena cava, KCO diffusing coefficient for carbon monoxide, lc limited cutaneous, NYHA New York Heart Association, RA right atrium, RV right ventricle, sBP systolic blood pressure, SD standard deviation, sPAP systolic pulmonary arterial pressure, SpO 2 peripheral oxygen saturation, SSc systemic sclerosis, TLC total lung capacity, TRV tricuspid regurgitation velocity, Δ variation of